# A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer

> **NCT07739758** · PHASE3 · RECRUITING · sponsor: **MediLink Therapeutics (Suzhou) Co., Ltd.** · enrollment: 442 (estimated)

## Conditions studied

- SCLC, Extensive Stage

## Interventions

- **DRUG:** YL201
- **DRUG:** Serplulimab
- **DRUG:** Carboplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT07739758
- **Lead sponsor:** MediLink Therapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-18
- **Primary completion:** 2029-06
- **Final completion:** 2030-04
- **Target enrollment:** 442 (ESTIMATED)
- **Last updated:** 2026-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07739758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07739758, "A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07739758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*